Australian biotechnology company BresaGen Ltd today received clarification about proposed changes to export and customs regulations following the recent Senate approval of Bills for Research Involving Embryos and Prohibition of Human Cloning.
The company has been informed by the National Health and Medical Research Council that there is no intention to prohibit the export of embryonic stem cells or the products of embryonic stem cells.
The regulatory changes only are intended to stop the export of whole embryos. BresaGen is encouraged by such an approach, as these changes will not hinder the development of embryonic stem cell based therapies in Australia for export to world markets.
BGN Price at posting:
0.0¢ Sentiment: None Disclosure: Held